Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02556151 · ClinicalTrials.gov registry record · NA

Neuromodulation Therapy for Fecal Incontinence

A NA study, sponsored by Augusta University.

Completed
Registry status
NA
Development phase
44
Enrollment target

NCT02556151: Completed NA study, sponsored by Augusta University.

NCT02556151 is a NA study that has completed, run by Augusta University. The registered enrollment target is 44 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02556151, a NA study, has completed, sponsored by Augusta University.

COMPLETED
Registry status
NA
Development phase
44 participants
Enrollment target

Study Summary

Fecal Incontinence (FI) affects 8-15 % of the US population, predominantly women and elderly, and 45% of nursing home residents. It significantly impairs quality of life and poses a major health care burden. FI is characterized by significant neuromuscular dysfunction of the pelvic floor that includes bilateral lumbo-anorectal and sacro-anorectal neuropathy and sensori-motor dysfunction. This multifactorial etiology suggests that maladaptive neuroplastic changes in the neural innervation of lower gastrointestinal tract could play a significant role in the pathogenesis of FI. A critical barrier to progress in the treatment of FI is the lack of understanding of how treatments affect the core pathophysiological mechanisms of FI, and the absence of mechanistically based non-invasive therapies. Our goal is to address the problem of FI by developing therapies that modulate peripheral and central neuronal perturbations and thereby improve visceromotor control and sensori-motor dysfunctions, and to understand the neurobiologic basis of these treatments. Our central hypothesis is that a novel non-invasive treatment consisting of repetitive translumbar magnetic stimulation (rTLMS) and repetitive transsacral magnetic stimulation (rTSMS) will significantly improve FI by enhancing peripheral and central neural excitability and will provide a multidimensional therapeutic benefit- enhance anal muscle strength, improve stool perception and improve rectal capacity. Our approach is based on our preliminary studies which suggest that repetitive translumbar magnetic stimulation (rTLMS) and transsacral magnetic stimulation (rTSMS) improve anorectal pain and neuropathy and induce central neuroplastic changes. Our objectives are to: 1. address the significant gap in our knowledge regarding the peripheral and central neuroenteric axis and how perturbations in the afferent and efferent neural signaling can affect FI; 2. develop a new treatment for FI with repetitive magnetic stimulation a

Primary Outcome

The primary outcome measure will be the reduction in number of episodes of Fecal incontinence from baseline to post treatment.

Interventions

  • PROCEDURE Repetitive lumbosacral magnetic stimulation (rTLSMS)

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2015-04
Est. Completion 2018-12-31
Phase NA
Augusta University

106 total trials

What the finished NCT02556151 record still lists

NCT02556151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which Repetitive lumbosacral magnetic stimulation (rTLSMS) is the first listed.

NCT02556151 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02556151 about?

NCT02556151 is a clinical study titled "Neuromodulation Therapy for Fecal Incontinence". Fecal Incontinence (FI) affects 8-15 % of the US population, predominantly women and elderly, and 45% of nursing home residents. It significantly impairs quality of life and poses a major health care burden. FI is characterized by significant neuromuscular dysfunction of the pelvic floor that includ...

What is the current status of trial NCT02556151?

This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2015-04. Estimated completion is 2018-12-31.

What interventions are being tested in trial NCT02556151?

The interventions under investigation include: Repetitive lumbosacral magnetic stimulation (rTLSMS) (PROCEDURE).

Who is sponsoring clinical trial NCT02556151?

This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02556151's enrollment target sits among peer trials

44 1423rd of 2000 higher than 566 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02556151, the US trial registry maintained by the National Library of Medicine. NCT02556151 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.